SNS01-T Demonstrates Synergy with Lenalidomide in Cancer Model
04 January 2012 - 12:30AM
Business Wire
Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE
AMEX: SNT) announced today that the combination of lenalidomide and
SNS01-T, the subject of Senesco’s on-going multiple myeloma
clinical study, performs better than either treatment alone in
mouse xenograft models of human mantle cell lymphoma.
The results will be presented with the Company update during
Biotech Showcase 2012 at 10.30 a.m. on Wednesday, January 11, 2012
in Track C at the Parc 55 Wyndham Hotel, 55 Cyril Magnin Street in
San Francisco.
“It is extremely positive that SNS01-T appears to combine well
with lenalidomide in this in vivo model,” said Leslie J. Browne,
Ph.D., President and CEO of Senesco. “The results not only provide
further support for the use of SNS01-T in multiple myeloma and
other B-cell cancers, like mantle cell and large diffuse B-cell
lymphoma, but also suggest that combining lenalidomide and SNS01-T
could be considerably more efficacious than lenalidomide alone. In
addition the results provide guidance in the design of future
clinical studies.”
The Company recently reported that SNS01-T significantly
inhibits the growth of both human mantle cell and diffuse large
B-cell lymphomas in mouse xenograft models and that SNS01-T
enhances the in vitro potency of certain marketed products when
used in combination.
Study Results Summary
When SCID mice, implanted with an aggressive human mantle cell
lymphoma cell line (JVM2), were treated with either 15 mg/kg
lenalidomide (5 times weekly by intra-peritoneal injection) or
0.375 mg/kg SNS01-T (twice weekly by intravenous injection) there
was a growth delay of 4 days and 14 days, respectively. Mice
treated with a combination of both drugs using the same dose levels
and dosing regimens exhibited a tumor growth delay of 27 days (p
value = 0.0008).
The median survival of mice treated with control nanoparticles
was 21 days. Mice treated with lenalidomide or SNS01-T had a median
survival of 28 days (33 % increase) and 37 days (76 % increase),
respectively. Mice treated with the drug combination had a median
survival of 52 days, an increase in survival of 148 %. Survival
analysis using the Kaplan-Meier method revealed that treatment of
mice with the drug combination resulted in statistically
significant increases in survival compared to both SNS01-T (p value
= 0.002) and lenalidomide (p value = 0.007) alone.
About Multiple Myeloma
Multiple myeloma is an incurable cancer of plasma cells, a type
of white blood cell derived from B-lymphocytes, normally
responsible for the production of antibodies, in which abnormal
cells accumulate in the bone marrow leading to bone lesions and
interfering with the production of normal blood cells. Senesco was
previously granted orphan drug status for SNS01-T, the Company’s
lead drug candidate for treatment of multiple myeloma.
About Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a form of non-Hodgkin’s lymphoma
(NHL), constituting roughly 6 percent of all NHL cases in the
United States. It is considered an aggressive form of B-cell
lymphoma.
About Senesco Technologies, Inc.
Senesco, a leader in eIF5A technology, is running a clinical
study in multiple myeloma with its lead therapeutic candidate
SNS01-T, which targets B-cell cancers by selectively inducing
apoptosis by modulating eukaryotic, translation, initiation Factor
5A (eIF5A), which is believed to be an important regulator of cell
growth and cell death. Accelerating apoptosis may have applications
in treating cancer, while delaying apoptosis may have applications
in treating certain inflammatory and ischemic diseases. Senesco has
already partnered with leading-edge companies engaged in
agricultural biotechnology and is entitled to earn research and
development milestones and royalties if its gene-regulating
platform technology is incorporated into its partners’
products.
Forward-Looking Statements
Certain statements included in this press release are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Actual results could
differ materially from such statements expressed or implied herein
as a result of a variety of factors, including, but not limited to:
the ability of the Company to consummate additional financings; the
development of the Company’s gene technology; the approval of the
Company’s patent applications; the successful implementation of the
Company’s research and development programs and collaborations; the
success of the Company's license agreements; the acceptance by the
market of the Company’s products; the timing and success of the
Company’s preliminary studies, preclinical research and clinical
trials; competition and the timing of projects and trends in future
operating performance, the Company’s ability to comply with the
continued listing standards of the NYSE Amex, as well as other
factors expressed from time to time in the Company’s periodic
filings with the Securities and Exchange Commission (the "SEC"). As
a result, this press release should be read in conjunction with the
Company’s periodic filings with the SEC. The forward-looking
statements contained herein are made only as of the date of this
press release, and the Company undertakes no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Senesco (AMEX:SNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Senesco (AMEX:SNT)
Historical Stock Chart
From Sep 2023 to Sep 2024